Deals:
MaxCyte announced a partnership with Kamau Therapeutics.
Arvato Systems and Advanco launched a comprehensive partnership.
Revance Therapeutics said Crown Laboratories failed to start a tender offer by deadline, impacting the acquisition agreement.
Lifebit, a leading provider of federated Trusted Research Environment technology, and CanPath (the Canadian Partnership for Tomorrow’s Health), Canada’s largest population health study, proudly announce a strategic partnership
Kajeet and Avery Telehealth announced a strategic partnership.
FDA:
The FDA has approved Apple’s sleep apnea detection feature.
Roche won approval from the FDA for an injectable version of its multiple sclerosis therapy Ocrevus.
FDA approves Novartis Kisqali to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Lilly’s EBGLYSS (lebrikizumab-lbkz) won approval for adults and children 12 years and older with moderate-to-severe atopic dermatitis.
An alert about Astellas’ Veozah (fezolinetant), a medicine used to treat hot flashes due to menopause, was issued, stating that it can cause rare but serious liver injury.
The Eversense 365 Continuous Glucose Monitoring (CGM) system for people with diabetes was cleared.
Funding rounds:
Nura Bio raised $68 million.
Arzeda closed a $38 million oversubscribed funding round.
Industry news:
Cigna’s pharmacy benefit manager Express Scripts sued the Federal Trade Commission, demanding a retraction of a recent report critical of the companies that negotiate drug spending.
Burson, the global communications leader purpose-built to create value for clients through reputation, today announced the launch of Decipher Health, its new cognitive AI offering.
Short interest for healthcare stocks in S&P 500 increased during August end vs. last month, with Moderna being most shorted for the second consecutive time.
Hill Holliday launches new healthcare practice dubbed Quest.
Ascendis Pharma reported positive results from a Phase 3 study of Transcon CNP in children with achondroplasia, the most common form of dwarfism.
The World Health Organization said on Friday it had cleared Bavarian Nordic’s (BAVA.CO) mpox vaccine, the first such shot to be approved by the agency for containing the spread of the disease in badly hit African countries.
J&J‘s $260 million talc verdict was overturned in Oregon, with a new trial ordered.
Prime Therapeutics unveiled a new corporate vision and brand identity.
Consulting firm Blue Matter has acquired healthcare corporate communications and PR agency Sam Brown Inc.
